Robert K. Mahar

626 total citations
24 papers, 154 citations indexed

About

Robert K. Mahar is a scholar working on Statistics and Probability, Economics and Econometrics and Statistics, Probability and Uncertainty. According to data from OpenAlex, Robert K. Mahar has authored 24 papers receiving a total of 154 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Statistics and Probability, 8 papers in Economics and Econometrics and 8 papers in Statistics, Probability and Uncertainty. Recurrent topics in Robert K. Mahar's work include Meta-analysis and systematic reviews (8 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Advanced Causal Inference Techniques (7 papers). Robert K. Mahar is often cited by papers focused on Meta-analysis and systematic reviews (8 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Advanced Causal Inference Techniques (7 papers). Robert K. Mahar collaborates with scholars based in Australia, United States and Canada. Robert K. Mahar's co-authors include Jason Wasiak, Patrick Mahar, Maarten J. IJzerman, John B. Carlin, Brett J. Manley, Clare Whitehead, Bibhas Chakraborty, Katherine J. Lee, Myra B. McGuinness and J. A. Simpson and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and Cochrane Database of Systematic Reviews.

In The Last Decade

Robert K. Mahar

17 papers receiving 148 citations

Peers

Countries citing papers authored by Robert K. Mahar

Since Specialization

Citations

This map shows the geographic impact of Robert K. Mahar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert K. Mahar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert K. Mahar more than expected).

Fields of papers citing papers by Robert K. Mahar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert K. Mahar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert K. Mahar. The network helps show where Robert K. Mahar may publish in the future.

Co-authorship network of co-authors of Robert K. Mahar

This figure shows the co-authorship network connecting the top 25 collaborators of Robert K. Mahar. A scholar is included among the top collaborators of Robert K. Mahar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert K. Mahar. Robert K. Mahar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inverse probability weighted estimation of dynamic treatment regimen means in sequential multiple assignment randomised trials with missing data: a simulation study 2026 ·Trials ·(unknown), Robert K. Mahar, (unknown), Anurika De Silva, (unknown)	0
2	Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial 2025 ·The Lancet Infectious Diseases ·Sean Wei Xiang Ong, Ruxandra Pinto, Robert K. Mahar, Asgar Rishu, Joshua S. Davis, Robert Fowler, Steven Y. C. Tong, Nick Daneman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
3	Platform trials: key features, when to use them and methodological challenges 2025 ·The Medical Journal of Australia ·Robert K. Mahar, Steve Webb, Ian C. Marschner, Andrew Forbes, Katherine J. Lee	0
4	Making Sense of Hierarchical Composite End Points in Randomized Clinical Trials—A Primer for Infectious Diseases Clinicians and Researchers 2025 ·Clinical Infectious Diseases ·Sean Wei Xiang Ong, Robert K. Mahar, (unknown), Ruxandra Pinto, (unknown), Robert Fowler, Steven Y. C. Tong, Nick Daneman	1
5	Protocol for Fit4Transplant: iterative optimisation of an exercise prehabilitation service for haematological cancer patients using phase II adaptive trials and co-design 2025 ·BMC Cancer ·Camille E. Short, Lara Edbrooke, (unknown), Tamara L. Jones, Amit Khot, Robert K. Mahar, (unknown), (unknown), (unknown), Catherine L. Granger, Selina M. Parry, Linda Denehy	0
6	Optimising dynamic treatment regimens using sequential multiple assignment randomised trials data with missing data 2025 ·BMC Medical Research Methodology ·(unknown), Anurika De Silva, Katherine J. Lee, Robert K. Mahar, J. A. Simpson	1
7	Colorenal fistulae: a rare but fatal presentation of renal tuberculosis in a paediatric patient 2025 ·Journal of the Pakistan Medical Association ·(unknown), (unknown), Robert K. Mahar, (unknown), (unknown)	0
8	Review article: Primer for clinical researchers on innovative trial designs for emergency medicine 2024 ·Emergency Medicine Australasia ·Katherine J. Lee, Melissa Middleton, Robert K. Mahar	0
9	Evaluating the impact of a SIMPlified LaYered consent process on recruitment of potential participants to the Staphylococcus aureus Network Adaptive Platform trial: study protocol for a multicentre pragmatic nested randomised clinical trial (SIMPLY-SNAP trial) 2024 ·BMJ Open ·Sean Wei Xiang Ong, Todd C. Lee, Robert Fowler, Robert K. Mahar, Ruxandra Pinto, (unknown), (unknown), (unknown), Matthew P. Cheng, Emily G. McDonald, Jennie Johnstone, Dominik Mertz, Christopher Kandel, Ranjani Somayaji, Joshua S. Davis, Steven Y. C. Tong, Nick Daneman	1
10	TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate 2024 ·Clinical Microbiology and Infection ·(unknown), Susan C. Morpeth, Balasubramanian Venkatesh, Thomas Hills, Joshua S. Davis, Robert K. Mahar, (unknown), Mark Jones, (unknown), Steven Y. C. Tong, Jason A. Roberts	5
11	Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review 2024 ·Trials ·(unknown), Katherine J. Lee, (unknown), Clare Whitehead, Brett J. Manley, Robert K. Mahar	6
12	TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of nafamostat and camostat mesylate randomised clinical trials 2023 ·(unknown), Susan C. Morpeth, (unknown), Thomas Hills, Joshua S. Davis, Robert K. Mahar, (unknown), Mark Jones, (unknown), Steven Y. C. Tong, Jason A. Roberts	1
13	Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials: evaluating cancer clinical trial value 2023 ·Cost Effectiveness and Resource Allocation ·(unknown), Robert K. Mahar, (unknown), Mark Rosenthal, Maarten J. IJzerman	0
14	Statistical analyses of ordinal outcomes in randomised controlled trials: protocol for a scoping review 2023 ·Trials ·(unknown), Katherine J. Lee, Clare Whitehead, Brett J. Manley, Robert K. Mahar	8
15	Transparent reporting of adaptive clinical trials using concurrently randomised cohorts 2023 ·SHILAP Revista de lepidopterología ·Ian C. Marschner, Mark Jones, (unknown), Robert K. Mahar, Tom Snelling, Steven Y. C. Tong	3
16	Improving clinical trials using Bayesian adaptive designs: a breast cancer example 2022 ·BMC Medical Research Methodology ·Wei Hong, Sue‐Anne McLachlan, Melissa M. Moore, Robert K. Mahar	5
17	A scoping review of studies using observational data to optimise dynamic treatment regimens 2021 ·BMC Medical Research Methodology ·Robert K. Mahar, Myra B. McGuinness, Bibhas Chakraborty, John B. Carlin, Maarten J. IJzerman, J. A. Simpson	16
18	Methodological quality assessment of paper-based systematic reviews published in oral health 2015 ·Clinical Oral Investigations ·Jason Wasiak, (unknown), (unknown), Robert K. Mahar, Gabor Abellán van Kan, (unknown), Clóvis Mariano Faggion	13
19	Interventions for reducing wrong-site surgery and invasive clinical procedures 2015 ·Cochrane Database of Systematic Reviews ·(unknown), Robert K. Mahar, Jason Wasiak, Lachlan M. Batty, Russell L. Gruen, Patrick Mahar	13
20	New approaches for the prevention of airway infection in ventilated patients. Lessons learned from laboratory animal studies at the National Institutes of Health. 2003 ·PubMed ·Lorenzo Berra, Mauro Panigada, Lorenzo De Marchi, Giacomo Greco, (unknown), Andrea Baccarelli, Joshua R. Pohlmann, (unknown), (unknown), Robert K. Mahar, Robert J. Lewandowski, (unknown), Theodor Kolobow	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact